Effects of three different kininase II inhibitors on blood pressure and renal vasoactive substances in essential hypertensives.
D015097:3-Mercaptopropionic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002216:Captopril / Q000627:therapeutic use*; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D007610:Kallikreins / Q000652:urine; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D007705:Kinins / Q000652:urine; D008297:Male; D008875:Middle Aged; D011674:Pulse / Q000187:drug effects; D012083:Renin / Q000097:blood; D013438:Sulfhydryl Compounds; D053778:Thiazolidines
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007705:Kinins; D013438:Sulfhydryl Compounds; D053778:Thiazolidines; D004656:Enalapril; D002216:Captopril; D015097:3-Mercaptopropionic Acid; C033437:rentiapril; D007610:Kallikreins; D012083:Renin